Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Target Oncol
; 11(3): 383-400, 2016 06.
Article
in En
| MEDLINE
| ID: mdl-26706237
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organoplatinum Compounds
/
Recombinant Fusion Proteins
/
Camptothecin
/
Antineoplastic Combined Chemotherapy Protocols
/
Receptors, Vascular Endothelial Growth Factor
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Target Oncol
Journal subject:
NEOPLASIAS
Year:
2016
Document type:
Article
Affiliation country:
Bélgica
Country of publication:
Francia